Preliminary brief— based on press release only. Full analysis including management tone and Q&A will be added when the transcript is available.

OXY · Q3 2025 Earnings

Occidental Petroleum

Reported November 10, 2025

30-second summary

Occidental sold OxyChem and used the call to recast itself as a pure-play U.S. upstream operator with 83% domestic production and a sub-$15B debt target. Q3 production of 1,465 Mboed beat the high end of the guide, FY Midstream & Marketing earnings were raised ~$400M above original guidance, and a preliminary 2026 capex framework of $6.3–6.7B landed alongside up-to-$400M of Permian short-cycle reallocation. The tone has fully shifted from deleveraging-grind to portfolio-optionality — but the share repurchase language softened, and OxyChem's standalone FY trajectory is now hard to read.

Headline numbers

EPS

Q3 FY2025

$0.64

Revenue

Q3 FY2025

$6.62B

-12.2% YoY

Free cash flow

Q3 FY2025

$1.50B

Key financials

Q3 FY2025

Metric	Q3 FY2025	YoY
Revenue	$6.62B	-12.2%
EPS	$0.64	—
Free cash flow	$1.50B	—

Guidance

Strong Q3 production beat; FY2025 Midstream & Marketing earnings raised $400M above original guidance; FY2026 capex framework ($6.3–$6.7B) and OxyChem sale debt/interest targets disclosed.

Guidance is issued for the full year only, refreshed each quarter. Prior and new below are the same FY updated this quarter.

Actuals vs prior guidance

Metric	Period	Prior guide	Actual	Δ	Result
Total company oil and gas production	Q3 FY2025	1.42 to 1.46 million BOE per day	1.465 million BOE per day	at high end of guide	Beat
Adjusted effective tax rate	Q3 FY2025	approximately 32%	approximately 32%	in-line	Met

New guidance

Metric	Period	Guide	YoY
Total company oil and gas capital expenditures	FY2026	$6.3 billion to $6.7 billion	—
U.S. onshore capital reallocation to short-cycle projects	FY2026	up to $400 million	—
Gulf of America and Oman capital allocation increase	FY2026	approximately $250 million	—
Principal debt balance target	Post-OxyChem sale (FY2025–2026 period)	principal debt less than $15 billion	—
Expected annual interest expense reduction	Post-OxyChem sale (FY2025–2026 period)	more than $350 million	—
Total company oil and gas production	Q4 FY2025	1.46 million BOE per day (midpoint)	—
OxyChem pre-tax income	Q4 FY2025	$140 million	—

Changes to prior guidance

Metric	Period	Prior guide	New guide	Δ	Result
Midstream and marketing pre-tax income	FY2025	$800–$900 million (OxyChem) + $85 million upside (Midstream & Marketing)	approximately $400 million above original guidance (FY2025)	approximately $400 million above original	Raised

Segment KPIs

Q3 FY2025

Segment	Q3 FY2025	YoY
Chemical (OxyChem)	$1.166B	-4.9%
Midstream & Marketing	$0.306B	-30.5%

Other KPIs

Q3 FY2025

Segment	Q3 FY2025
Total Company Average Production	1,465 Mboed
Permian Production	800 Mboed
Rockies & Other Domestic Production	288 Mboed
Gulf of America Production	139 Mboed
International Production	238 Mboed
Worldwide Realized Crude Oil Price	$64.78/bbl
Operating Cash Flow Before Working Capital	$3.2 billion
Principal Debt Balance	$20.8 billion

Management tone

Q1 (Crown Rock integration grind) → Q2 (debt paydown ahead of plan, DAC commercial) → Q3 (portfolio transformation declared complete, OxyChem sold).

OxyChem went from "core diversifier under cyclical pressure" to "legacy holding to monetize" in a single quarter. Q2 framed the $800–900M OxyChem guide cut as a Chinese-export-driven cyclical issue worth weathering. This quarter Holub said the sale "was driven by the scale, quality, and diversity of the oil and gas portfolio we have built over the last decade…we're done with…anything that's any big acquisitions or anything like that." That's a full strategic recategorization, not a tactical divestiture — and it removes the OxyChem-floor question from the Q2 watch list entirely.

Capital allocation language shifted from offensive to flexible-defensive. Last quarter the read was that, with Crown Rock debt ~70% retired, the next conversation would be about growth optionality and buybacks. This quarter the framing is "we're not going to aggressively put lots of extra barrels into an oversupplied market" and "any additional allocation of capital next year will be undertaken in a thoughtful manner." The $6.3–6.7B 2026 capex range with reallocation flexibility — and the explicit $55–60 WTI planning anchor — read as a company hedging against a softer commodity tape, not pressing into it.

Share repurchase commitment softened materially. Q2's tone implied buybacks were imminent post-deleveraging. Q3's language: "we will be opportunistic with the share repurchase program, driven by macro conditions, commodity prices, market valuation, and timeline to August 2029." Three conditional gates plus a deadline reference is meaningfully weaker than the prior quarter's posture. The Q2 watch list item on "capital return signaling" got an answer — and the answer is that buybacks are not the next-up use of OxyChem proceeds; debt reduction to <$15B is.

Resource narrative restructured from inventory to recovery factor. Richard Jackson: "moving to more of a resource explanation was a better representation of what we are and the value that we have." The pivot to total resource (16.5B BOE Permian) plus unconventional CO2 EOR as a 45%-to-100% uplift opportunity is consistent with Q2's directional message but is now the lead narrative rather than a sidebar. This is a multi-quarter setup — management is preparing the investor base for a story that depends on subsurface technology, not rig count.

Geopolitical risk reframed as a competitive advantage. "We now have a higher quality portfolio with Oxy's lowest ever geopolitical risk as we have shifted the percentage of our oil and gas production from 50% domestic to 83% domestic." This sentence didn't exist in Q2 prepared remarks. It is positioning the stock for a re-rating against international-heavy peers and reflects management conviction that the transformation phase is over.

Recurring themes management leaned on this quarter:

Portfolio transformation complete: shift from diversified OxyChem/international to pure-play U.S. oil & gas with 83% domestic productionResource base expansion through subsurface characterization and advanced recovery (2.5B BOE added to Permian, 16.5B total)Cost efficiency as sustained competitive advantage ($2B annualized savings since 2023; 38% well cost reduction Midland Basin)Unconventional CO2 EOR as differentiated growth vector with recovery factor doubling potential (45% to 100% uplift)Balance sheet strengthening and debt reduction to sub-$15B target enabling capital flexibilityFree cash flow resilience across commodity price scenarios (flat to +2% production growth on $6.3-6.7B capex)

Risks management surfaced:

Oil market oversupply concerns constraining production growth decisionsGlobal chlor-vinyl market weakness impacting OxyChem earnings pre-divestitureCommodity price volatility and macro deterioration requiring capital reductionsScheduled turnarounds and facility maintenance timing impacts on production (Q4 Halusum turnaround)International production softness vs. domestic outperformance (mentioned as offsetting factor)

Answers to last quarter's watch list

OxyChem trajectory — Resolved, but not in the way the question anticipated: the segment is being sold. FY2025 standalone trajectory is no longer the right lens; Q4 segment pre-tax income guided to $140M, and ~$6.5B of sale proceeds are earmarked for debt reduction. The PVC/caustic cyclical floor question becomes moot for OXY shareholders.

Not resolved

Q3 production within 1.42–1.46 MMBoe/d — Came in at 1.465 MMBoe/d, above the high end. U.S. onshore overdelivery offset international softness; Q4 guide midpoint raised to 1.46 MMBoe/d. Clean beat.

Resolved positively

Stratos commissioning and first CO2 capture milestone — Not called out on the print or in management's prepared remarks summary; with the strategic narrative dominated by the OxyChem sale and 2026 capex framework, DAC commercial milestones did not get the airtime they received in Q2.

Continue monitoring

Capital return signaling — Answered, and the answer skews to debt reduction over buybacks. The <$15B principal debt target absorbs ~$6.5B of OxyChem proceeds first; share repurchase language is now explicitly conditional on "macro conditions, commodity prices, market valuation, and timeline to August 2029." Less shareholder-return certainty than Q2 implied.

Resolved negatively

Cash tax realization (~35% of $700–800M in 2025) — Not specifically updated in the disclosures available. Adjusted effective tax rate held at ~32% as previously guided.

Continue monitoring

Permian secondary bench and shale EOR progression — Substantially progressed: management quantified a >2 billion BOE unconventional CO2 EOR resource opportunity with 45%-to-100% production uplift potential, and reallocated up to $400M of 2026 capex toward short-cycle high-return Permian projects. No specific shale EOR project FID yet, but the framework moved from concept to capital.

Resolved positively

What to watch into next quarter

OxyChem sale close timing and use-of-proceeds discipline: Whether the full ~$6.5B actually flows to debt reduction or gets partially redirected. Slippage on the close, or any reallocation toward buybacks before <$15B principal debt is achieved, would change the credit story.

2026 capex landing within the $6.3–6.7B range and the macro-conditionality test: Whether the board-approved budget anchors near the low end (defensive) or high end (constructive on price). Any number below $6.3B would signal management is reading a weaker commodity tape than they let on.

Q4 production delivery vs. the 1.46 MMBoe/d midpoint and the Halusum turnaround impact: Specifically whether international weakness widens or U.S. onshore continues to absorb it. Coming in below midpoint would dent the "beat-and-raise" cadence the production guide has held for three quarters.

Share repurchase activity disclosed for Q4: Given the explicitly conditional language, any actual buyback executed this quarter would be informative — silence or a token amount would confirm the softer posture.

Unconventional CO2 EOR — first commercial project FID or dollar commitment: The 2B BOE resource and 100% uplift potential need a project to anchor them. Continued narrative-only treatment into Q4 would suggest the framework is further out than this quarter's pitch implied.

Midstream & Marketing run-rate post-Q3 outperformance: Whether the ~$400M FY beat reflects sustainable gas marketing and sulfur economics or one-time positioning. Q4 segment guidance and any FY2026 framing will tell.

Sources

Occidental Petroleum Q3 2025 earnings press release, filed November 10, 2025 — https://www.sec.gov/Archives/edgar/data/797468/000162828025051056/oxyex99109-30x25earningsre.htm
Occidental Petroleum Q3 2025 earnings conference call — prepared remarks from Vicki Holub (CEO), Sunil Mathew (CFO), Richard Jackson, and Ken Dillon. Forward guidance, OxyChem sale commentary, 2026 capex framework, and strategic narrative sourced from the call.

Get the next brief, free.

We publish analyst-grade earnings briefs the same day or morning after every call — headline numbers, segment KPIs, Q&A highlights, and tone analysis. Free during beta.

This is not investment advice.